V-Kardia

V-Kardia is a clinical-stage medical device company focused on developing innovative transcatheter therapies for heart failure. Incubated by Coridea, a prominent medical technology accelerator, the company is developing a percutaneous system designed to create a controlled interatrial shunt. This "pressure-relief valve" approach aims to reduce elevated left atrial pressure, which is a primary cause of pulmonary congestion and exercise intolerance in patients with both preserved (HFpEF) and reduced (HFrEF) ejection fraction. By providing a mechanical solution to hemodynamic imbalances, V-Kardia seeks to improve clinical outcomes and quality of life for the millions of patients suffering from chronic heart failure. The company leverages the expertise of its founders in cardiovascular physiology and interventional cardiology to address significant unmet needs in the heart failure market.